➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
Merck
Colorcon
Boehringer Ingelheim

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Agalsidase beta - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for agalsidase beta
Tradenames:1
Patents:21
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for agalsidase beta
Recent Clinical Trials for agalsidase beta

Identify potential brand extensions & biosimilar entrants

SponsorPhase
SanofiPhase 4
University Hospital, RouenN/A
Amicus TherapeuticsPhase 2

See all agalsidase beta clinical trials

Pharmacology for agalsidase beta
Ingredient-typealpha-Glucosidases

Company Disclosures: US Patents for agalsidase beta

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 002 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for agalsidase beta

These patents were identified by searching patent claims

Supplementary Protection Certificates for agalsidase beta

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0627 Netherlands   Start Trial PRODUCT NAME: METHOD FOR PRODUCING SECRETED PROTIENS; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803
C/GB13/069 United Kingdom   Start Trial PRODUCT NAME: AGALSIDASE BETA; REGISTERED: UK EU/1/01/188/001 20010807; UK EU/1/01/188/002 20010807; UK EU/1/01/188/003 20010807; UK EU/1/01/188/004 20010807; UK EU/1/01/188/005 20010807; UK EU/1/01/188/006 20010807
0452 Netherlands   Start Trial PRODUCT NAME: AGALSIDASE ALFA; REGISTRATION NO/DATE: EU/1/01/189/001 20010807
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
Boehringer Ingelheim
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.